Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126202302 | 12620230 | 2 | F | 20160822 | 20160803 | 20160902 | EXP | GB-MHRA-MIDB-14367D93-B290-47C0-81DD-598791716A67 | GB-TEVA-679684ACC | TEVA | 47.00 | YR | F | Y | 0.00000 | 20160902 | PH | GB | GB |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126202302 | 12620230 | 1 | PS | LANSOPRAZOLE. | LANSOPRAZOLE | 1 | Oral | Y | U | 77255 | |||||||||
| 126202302 | 12620230 | 2 | SS | VENLAFAXINE | VENLAFAXINE HYDROCHLORIDE | 1 | Oral | 75 MILLIGRAM DAILY; REDUCED TO 37.5MG. | Y | U | 0 | 75 | MG | TABLET | QD | ||||
| 126202302 | 12620230 | 3 | SS | FUROSEMIDE. | FUROSEMIDE | 1 | Oral | 160 MILLIGRAM DAILY; | Y | U | 0 | 80 | MG | TABLET | BID | ||||
| 126202302 | 12620230 | 4 | C | CETIRIZINE | CETIRIZINE HYDROCHLORIDE | 1 | Oral | 10 MILLIGRAM DAILY; | 0 | 10 | MG | TABLET | QD | ||||||
| 126202302 | 12620230 | 5 | C | CHLORHEXIDINE GLUCONATE SOLUTION | CHLORHEXIDINE GLUCONATE | 1 | Topical | SOAP SUBSTITUTE | 0 | ||||||||||
| 126202302 | 12620230 | 6 | C | CLOTRIMAZOLE. | CLOTRIMAZOLE | 1 | Topical | 2 DOSAGE FORMS DAILY; | 0 | 1 | DF | CREAM | BID | ||||||
| 126202302 | 12620230 | 7 | C | DIPROBASE | CHLOROCRESOL | 1 | Topical | 0 | CREAM | ||||||||||
| 126202302 | 12620230 | 8 | C | NYSTATIN. | NYSTATIN | 1 | Oral | 4 ML DAILY; STRENGTH: 100,000UNITS/ML | 0 | 1 | ML | ORAL SUSPENSION | QID | ||||||
| 126202302 | 12620230 | 9 | C | OMEPRAZOLE. | OMEPRAZOLE | 1 | Oral | 20 MILLIGRAM DAILY; | 0 | 20 | MG | CAPSULE | QD | ||||||
| 126202302 | 12620230 | 10 | C | PARACETAMOL | ACETAMINOPHEN | 1 | Oral | 500MG-1G EVERY 4-6HOURS | 0 | TABLET |
Indications of drugs used
| no results found |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126202302 | 12620230 | OT |
| 126202302 | 12620230 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126202302 | 12620230 | Acute kidney injury | |
| 126202302 | 12620230 | Chest pain | |
| 126202302 | 12620230 | Diarrhoea | |
| 126202302 | 12620230 | Dyspnoea | |
| 126202302 | 12620230 | Loss of consciousness |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |